Connect with us


Grow Pharma to launch own-brand cannabis flower

Grow Pharma launches own-brand products to improve accessibility of prescribed cannabis medicines



Grow Group recently completed acquisition of a major cultivation and extraction facility located in Spain

Grow Pharma has announced it will launch its own range of medical cannabis flowers to improve accessibility of prescribed cannabis medicines.

Leading supplier of prescribed cannabis medicines, Grow Pharma, announced today the launch of their own brand of medical cannabis flowers for UK patients.

This will start with a mid-range THC sativa and a balanced-ratio hybrid with a third, indica flower, to follow in the coming weeks.

The UK medical cannabis market is still in its infancy, with many patients now receiving prescribed medical cannabis, since moving  to regulated, safer and legally prescribed products with medical oversight of their treatment.

Grow Pharma new cannabis products

Many of these patients have a broad knowledge of the cannabis plant and its active ingredients and are very often used to certain cultivars (strains) that are providing the best relief for their symptoms. In order to cater for both these “experienced” patients and for the other side of the coin; the “cannabis naïve” patients, Grow Pharma aims to have the broadest possible range of cannabis medicines available for doctors and patients.

Towards that aim Grow recently launched capsules and is constantly looking into new modes of administration. Soon the company will launch medical cannabis vape (oil) pens with their partner, Columbia Care, who also introduced the capsules.

The launch of the Grow flower medicines fits this narrative. The cultivars and cannabinoid ratios will be in addition to Grow’s range of premium branded products from Aurora and Tilray, further increasing the options available for patients. 

Pricing is moderate and will allow patients to use only these products or combine premium brands with Grow’s own quality brand to create the optimal symptom management for patients who have exhausted other pharmaceutical options or are suffering too many side effects from these medications. 

Grow’s focus on patients also means that, as with the other brands, there is a consistent and sustainable supply of these products via their pharmacy partners, IPS Pharma.

Grow and IPS already represent world-renowned producers of medical cannabis Aurora, Tilray and Columbia Care and recently signed an agreement with ALT to bring their liquid medical cannabis products to Europe early next year.

Grow Pharma

Grow has the broadest range of cannabis medicines in the UK, with 20 flower and 25 oil medicines, including these new additions, as well as the capacity to formulate oils with bespoke ratios of THC and CBD where required. They are also the only UK supplier to stock a range of hard-shell medical cannabis capsules, manufactured locally for USA producer Columbia Care.

“Cannabis medicines are so personal to the individual patient; this is why it’s important for us to ensure doctors have a wide-range of options to choose from when treating patients,” commented GROW’s patient access lead and prominent medical cannabis advocate, Alex Fraser.

“We already have the widest range prior to the addition of the GROW Flowers, but we felt we needed to offer more options alongside the flower ranges we stock from  Aurora and Tilray, to ensure that even more patients can benefit from these medicines and the fast and efficient pharmacy service IPS provide.

With prescription numbers for cannabis medicines in the UK increasing month-on-month and more doctors entering the space, it is no surprise to see a company like Grow launching its own brand.

However, GROW CEO Pierre Van Weperen stated: “One of the things that makes us the supplier of choice for doctors prescribing cannabis medicines is that we provide a wide range from multiple leading producers. This means the doctors we support can make the best decisions for their patients and we can ensure consistency in the supply of patient’s medicines.

“We continue to see enormous benefit of supplying medicines from multiple reputable producers. The globally leading brands are all working with us and together we are all working on driving access for patients to these products. There are several hundred thousand UK patients out there who would potentially benefit from these cannabis medicines. The introduction of our GROW flowers brand will only strengthen our broad offering and these efforts”.

Grow Pharma’s parent company Grow Group recently completed an acquisition of Sanoid Isolates, a major cultivation and extraction facility located in Seville, Spain where Grow intends to breed unique cultivars and produce new medicines based on the needs of doctors and patients.

Doctors can find information on the medicines GROW supplies by contacting them directly or by signing up to the recently launched HCP Portal where they can also speak privately to other doctors in the field and find out about the latest educational events on medical cannabis for healthcare professionals.

CBD and CBG: A black banner saying that the content has been created with sponsors

READ MORE  US officials call for change in rules around cannabis in sport


Study: States with full legal access show fewer registered medical cannabis patients

“If true, this could have implications for public health and policy,” say researchers.



Study shows U.S states where cannabis is legal for recreational purposes have experienced a decrease in patients registering for medical cannabis programmes.

The study on different US states, published in the International Drug Journal, revealed that numbers of registered and active medical cannabis consumers increased while it was not legal for recreational use.

Researchers in Arizona took data from the medical cannabis registry from two dozen states between 2013 and 2020.  These are mandatory registries that record the number of medical cannabis patients. They analysed the data to see if there were any changes around the times that recreational legalisation was introduced.

There are currently 19 states in the US that have legalised recreational cannabis including New Jersey, Vermont, Arizona and New York. However, more states have medical cannabis programs although some are still not operational. Some states such as Colorado have had recreational access since 2012, the year before the study was started.

Medical cannabis patients

The results confirmed that medical cannabis cardholders increased during times when recreational use was not legal. It then subsequently decreased when it became legal.

It also revealed an increase of 380 patients per 100,000 people per year when just medical cannabis was legal. This corresponded to a decrease of 100 patients per 100,000 after recreational cannabis was allowed. The researchers noted that active registered active male patients decreased faster than women. In states where only medical cannabis was legal, the older age groups (35 or older), increased faster.

They also found that in three states with medical-only use, the results showed significant increases in enrollment from 2016 to 2020 across white, African-American and Hispanic patients.

READ MORE  Making the case for medical cannabis vaping

The researchers wrote: “There is speculation that enrollment in U.S. state medical cannabis programs differs depending on whether adult recreational cannabis use is legal. If true, this could have implications for public health and policy.”

“Findings suggest that recreational cannabis legalisation is associated with decreasing enrollment in medical cannabis programs, particularly for males.”

Medical Cannabis: A banner advert for subscribing to cannabis health

Continue Reading


Latin American cannabis clinic Zerenia arrives in UK – promising patients more ‘affordable’ access

The clinic has recently joined Project Twenty21 with the promise of making medical cannabis more accessible.



Zerenia clinic: doctor holding medical cannabis
The clinic will initially prescribe for chronic pain and mental health conditions.

Latin American medical cannabis clinic, Zerenia, has launched in the UK, with a bid to improve patient access as it joins Project Twenty21.

Zerenia Clinics, which launched in the UK in recent weeks, has joined a growing number of clinics on Project Twenty21 (T21), as it aims to make medical cannabis more affordable for patients. 

The clinic also offers competitive costs, with consultation fees at £80. 

The clinic’s three doctors will initially prescribe for chronic pain and mental health, with the majority of patients so far seeking treatment for indications such as anxiety, ADHD, PTSD and insomnia.

Zerenia, which already has 14 clinics across Latin America, has treated around 14,000 patients with medical cannabis, and according to Zerenia’s UK clinical operations director, Freeda Solliman, mental health is the predominant indication prescribed for. 

Many of these patients now get their prescriptions funded via private insurers, a model which the clinic now hopes to replicate in the UK. 

“In Latin America we’ve built a body of evidence there to support private insurers to fund medical cannabis treatment,” Solliman told Cannabis Health.

“We’ve seen about 14,000 patients who have been treated with medical cannabis and a large number of those actually get their prescriptions funded by private insurers. That’s the kind of model that you want to bring here.”

Zerenia has partnered with T21, which subsidises the cost of prescriptions, to help build the growing body of evidence for the safety and efficacy of medical cannabis. 

“Our goals are quite well aligned, we want to build the evidence and we want to make medical cannabis more affordable for patients,” continued Solliman.

“We want to work to encourage the NHS first and foremost, but also private insurers to fund at least part of the costs involved in being treated with medical cannabis.”

She added: “We did our research to understand some of the bottlenecks in the industry and how hard it is for some patients to go through the process, so we wanted to support patients through that and try to offer them more of a seamless experience.”

Zerenia is now taking on new patients who wish to join T21, or those who may want to try a different clinic. 

Initial consultations for new patients are priced at £80, for those transfering from a different clinic, £40. Find more information here

READ MORE  Twitter’s Katie Ford joins Fyllo to focus on cannabis sector
Continue Reading


CiiTECH to launch medicinal cannabis range Provacan THC in Israel

Israeli patients will have access to the first Provacan THC oil in January 2022, followed by Brazilian and British patients.



CiiTECH: The logo for Ciitech

CiiTECH and Cannassure have announced a major deal to develop and market Provacan THC products for medical cannabis use in Israel.

It marks CiiTECH’s long-awaited move into medicinal cannabis.

In addition to offering established consumer CBD brands, CiiTECH’s flagship brand Provacan is considered one of the most respected in the UK.

Clifton Flack, CEO and founder of CiiTECH, intends to bring Provacan’s reputation for quality and consistency to the troubled Israeli medical cannabis market.

“CiiTECH is unique in its approach to the CBD wellness and medicinal cannabis markets. We built an international reputation as a market-leading CBD company by producing pharmacy trusted CBD oil tinctures and selling them as food supplements before making our move into THC. Our intention is to bring these International standards to the Israeli market,” says Flack.

“As a UK company with strong roots in Israel, CiiTECH is well-positioned to make its THC debut and there is no better place to do so than in Israel, the epicentre of global cannabis research.”

Cannassure is known for producing high-grade medical cannabis in Israel with an advanced indoor-aeroponic growing system and state-of-the-art extraction.”

CiiTECH collaboration

The collaboration with CiiTECH, a leading company in the field of cannabis research and marketing and owner of the leading brand Provacan, is an important step in the field of cannabis oils for us, an area that enjoys significant growth among patients who do not want to consume inflorescence cannabis. We are confident that this collaboration will bring value for us, for CiiTECH and for cannabis patients in Israel, and we believe that it will help us conquer a more significant share of the cannabis oil market in Israel,” said Ran Amir, Cannassure CEO.

READ MORE  New North Macedonian facility to export medical cannabis extracts to global markets

As part of its business strategy, CiiTECH seeks and collaborates with best-of-breed cannabis providers up and down the supply chain in multiple geographies. With this agreement, CiiTECH continues to demonstrate its effective business strategy, commitment to quality assurance, and speed of entry into the market that the industry has grown to expect from CiiTECH.

With the help of Cannassure, CiiTECH will help reform, standardise, educate and establish quality, consistency, and reliability in the Israeli medical cannabis market. In order to achieve this goal, CiiTECH is developing a hybrid solution in which a superior quality product is offered to patients and a unique professional enrichment program is offered to help doctors and pharmacists support patients on a deeper level.

CiiTECH education

Around 80 per cent of Israel’s 100,000 licensed medical cannabis users smoke, rather than using tinctures. The biggest complaint in those groups is the lack of quality and consistency. It is CiiTECH’s mission to show these users how much better tinctures are than smoking. Provacan ambassadors and users will benefit from comprehensive education courses provided by CiiTECH as part of this re-education so they will feel more confident and better supported while using CiiTECH products.

“As cannabis market experts and our involvement in the cannabis ecosystem in Israel, we understand the nature of the demand and the gaps in the Israeli market. Our new THC tincture will revolutionise the lives of many patients who are currently suffering from inconsistencies in the medical cannabis supply chain, and it will be made to the same strict UK and European guidelines as our current products,” concluded Flack.

READ MORE  Cannabis legalisation not linked to rise in car accidents, says study

Israeli patients will have access to the first Provacan THC oil in January 2022, followed soon by Brazilian and British patients.

Ciitech: A banner advertising collaborative content

Continue Reading